Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Chou

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Science Immunology|April 4, 2017
Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8<sup>+</sup> T Cells <i>In Vivo</i>Aude G Chapuis, Cindy Desmarais, Ryan Emerson, et al.
JCI Insight|May 24, 2016
Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamideChristopher G Kanakry, David G Coffey, Andrea M H Towlerton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patientsScott S Tykodi, Nobuharu Fujii, Nathalie Vigneron, et al.
Cancer Communications (London, England)|July 22, 2025
Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitorsHarriet Kluger, Götz Ulrich Grigoleit, Sajeve Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic CancersAdi Diab, Omid Hamid, John A Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 StudyTheresa Medina, Jason A Chesney, Harriet M Kluger, et al.
Molecular Cancer Therapeutics|August 28, 2020
Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 AntibodyAmir A Al-Khami, Sawsan Youssef, Yasmina Abdiche, et al.
Journal for Immunotherapy of Cancer|October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumorsOmid Hamid, Alberto A Chiappori, John A Thompson, et al.
Journal for Immunotherapy of Cancer|August 25, 2025
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinomaRobert L Ferris, Rom S Leidner, Christine H Chung, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Science Immunology|April 4, 2017
Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8<sup>+</sup> T Cells <i>In Vivo</i>Aude G Chapuis, Cindy Desmarais, Ryan Emerson, et al.
JCI Insight|May 24, 2016
Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamideChristopher G Kanakry, David G Coffey, Andrea M H Towlerton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patientsScott S Tykodi, Nobuharu Fujii, Nathalie Vigneron, et al.
Cancer Communications (London, England)|July 22, 2025
Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitorsHarriet Kluger, Götz Ulrich Grigoleit, Sajeve Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic CancersAdi Diab, Omid Hamid, John A Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 StudyTheresa Medina, Jason A Chesney, Harriet M Kluger, et al.
Molecular Cancer Therapeutics|August 28, 2020
Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 AntibodyAmir A Al-Khami, Sawsan Youssef, Yasmina Abdiche, et al.
Journal for Immunotherapy of Cancer|October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumorsOmid Hamid, Alberto A Chiappori, John A Thompson, et al.
Journal for Immunotherapy of Cancer|August 25, 2025
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinomaRobert L Ferris, Rom S Leidner, Christine H Chung, et al.
Pageof 3